Whereas sclerosteosis patients have no detectable protein in circulation, heterozygous carriers of SOST mutations have serum sclerostin levels approximately half that of control subjects (84) and bone mineral density (BMD) values higher than age-matched controls (85). Here, SOST is linked to sclerosteosis.